Vaxart Shares Are Trading Higher After the Company Received a BARDA-funded Project NextGen Award Valued up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
vaxart股价上涨，公司获得了一项BARDA资助的NextGen项目，价值高达4.53亿美元，进行第2b期研究，评估其COVID-19口服疫苗候选者。